Bain verwendet Cookies, um die Funktionalität und Leistung dieser Website zu verbessern. Weitere Informationen finden Sie in unserer Datenschutzerklärung. Mit Nutzung dieser Website erklären Sie sich mit der Verwendung von Cookies einverstanden.

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

  • 4. Januar 2016
  • Min. Lesezeit

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

BioPharma Dive tapped into the expertise of top thought leaders in the industry to get their takes on what comes next in pricing, M&As, drug development, transparency and much more. "Bain has demonstrated how biopharma leaders have created the most shareholder value by focusing on a few, sustainable leadership positions in Product Categories (distinct from Therapeutic Areas)," said Ashish Singh, the leader of Bain & Company's Global Healthcare practice. "This focused strategy of Category Leadership has been proven to provide superior returns on investment in R&D and commercial."